Webinar on Driving Translational Imaging to a Drug Industry Standard: Case Studies in Glioblastoma and Other Clinically Predictive Cancer Models

Toronto, Canada (PRWEB) September 04, 2012

Medical imaging technologies can facilitate drug discovery, efficacy evaluation, and translation into the clinic. Now a maturing platform, molecular imaging is the catalyst for a new standard of how drug candidates are evaluated and advanced into trials.
By providing clinically translatable biomarkers as an accompaniment to standard measures of response, imaging leverages and amplifies the valuable data gathered during earlier stages of discovery and efficacy evaluation. A significant determinant of the clinical applicability of the obtained biomarker data is preclinical models that it is derived from. As a cornerstone of modern cancer drug discovery, a diverse array of preclinical cancer models are available, each with unique advantages and shortcomings.
Preclinical models are often criticized as being poorly predictive of success in the clinic. By choosing the proper models and pairing them with advancing imaging technologies, their predictive power can be improved.
For more information or to register go to http://xtks.in/xto-514.

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

PDF Print